Depomed, Inc. (NYSE:ASRT) Director Acquires $77,000.00 in Stock

Depomed, Inc. (NYSE:ASRT) Director Arthur J. Higgins bought 50,000 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average cost of $1.54 per share, for a total transaction of $77,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

NYSE:ASRT remained flat at $$1.52 during trading hours on Monday. 2,119,204 shares of the company traded hands, compared to its average volume of 843,380. Depomed, Inc. has a twelve month low of $1.49 and a twelve month high of $8.08. The company has a 50 day moving average of $3.04.

Several brokerages recently commented on ASRT. Mizuho decreased their target price on shares of Depomed from $6.00 to $3.00 and set a “neutral” rating on the stock in a research note on Thursday, May 16th. Zacks Investment Research cut shares of Depomed from a “buy” rating to a “hold” rating in a report on Monday, July 29th.

An institutional investor recently raised its position in Depomed stock. BNP Paribas Arbitrage SA grew its holdings in shares of Depomed, Inc. (NYSE:ASRT) by 11,153.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,379 shares of the company’s stock after buying an additional 12,269 shares during the period. BNP Paribas Arbitrage SA’s holdings in Depomed were worth $63,000 as of its most recent SEC filing.

About Depomed

Assertio Therapeutics, Inc, a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults.

Read More: What is meant by holder of record?

Insider Buying and Selling by Quarter for Depomed (NYSE:ASRT)

Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit